C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 175, Issue 3, 2007, Pages 250-255

  Dahl, Morten ^b   Vestbo, Jørgen ^b   Lange, Peter ^b   Bojesen, Stig E ^b   Tybjærg Hansen, Anne ^b   Nordestgaard, Børge G ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b NONE

Author keywords

Airway obstruction; Biological markers; Cohort study; Inflammation; Lung diseases, obstructive

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HAZARD RATIO; HOSPITALIZATION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK ASSESSMENT; SMOKING; STATISTICAL ANALYSIS;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK;

EID: 33846785205     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200605-713OC     Document Type: Article

References (49)

1. Pauwels R, Buist A, Calverley P, Jenkins C, Hurd S. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276.
2. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004;364:613-620.
3. Wouters EFM. A wasting disease. In: Voelkel NF, MacNee W, editors. Chronic obstructive lung disease. Hamilton, ON, Canada: B.C. Dekker; 2002. pp. 364-376.
4. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347-360.
5. Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-580.
6. Landbo C, Prescott E, Lange P, Vestbo J, Almdal T. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1856-1861.
7. Schols AM, Slangen J, Volovics L, Wouters EFM. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1791-1797.
8. Agusti AG, Sauleda J, Miralles C, Gomez C, Togores B, Sala E, Batle S, Busquets X. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:485-489.
9. Vestbo J, Prescott E, Almdal T, Dahl M, Nordestgaard BG, Andersen T, Sørensen TIA, Lange P. Body mass, fat-free body mass, and prognosis in patients with COPD from a random population sample. Am J Respir Crit Care Med 2006;173:79-83.
10. Mold C, Rodic-Polic B, Du Clos TW. Protection from Streptococcus pneumoniae infection by C-reactive protein and natural antibody requires complement but not Fcγ receptors. J Immunol 2002;168:6375-6381.
11. Weiser JN, Pan N, McGowan KL, Musher D, Martin A, Richards J. Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J Exp Med 1998;187:631-640.
12. van Tits L, de Graaf J, Toenhake H, van Heerde W, Stalenhoef A. C-reactive protein and annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 2005;25:717-722.
13. Chang M-K, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 2002;99:13043-13048.
14. Gershov D, Kim S, Brot N, Elkon KB. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an anti-inflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2001;193:1439.
15. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004;116:9S-16S.
16. Kony S, Zureik M, Driss F, Neukirch C, Leynaert B, Neukirch F. Association of bronchial hyperresponsiveness and lung function with C-reactive protein (CRP): a population based study. Thorax 2004;59:892-896.
17. de Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, Muros de Fuentes M, Montejo de Garcini A, Aguirre-Jaime A, Celli BR, Casanova C. C-reative protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006;27:902-907.
18. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006;61:23-28.
19. Schnohr P, Jensen G, Lange P, Scharling H, Appleyard M. The Copenhagen City Heart Study - Østerbroundersøgelsen: tables with data from the third examination 1991-1994. Eur Heart J Suppl 2001;3(H):H1-H83.
20. Dahl M, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. A population-based study of morbidity and mortality in mannose-binding lectin deficiency. J Exp Med 2004;199:1391-1399.
21. Dahl M, Tybjaerg-Hansen A, Lange P, Nordestgaard BG. Asthma and COPD in cystic fibrosis intron-8 5T carriers: a population-based study. Respir Res 2005;6:113.
22. Seersholm N, Wilcke JTR, Kok-Jensen A, Dirksen A. Risk of hospital admission for obstructive pulmonary disease in α1-antitrypsin heterozygotes of phenotype PiMZ. Am J Respir Crit Care Med 2000;161:81-84.
23. Lange P, Nyboe J, Jensen G, Schnohr P, Appleyard M. Ventilatory function impairment and risk of cardiovascular death and of fatal or non-fatal myocardial infarction. Eur Respir J 1991;4:1080-1087.
24. Ridker P. Clinical application of c-reactive protein for cardiovascular disease and prevention. Circulation 2003;107:363-369.
25. Man P, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006;61:849-853.
26. van Helvoort HA, van de Pol MH, Heijdra YF, Dekhuijzen PN. Systemic inflammatory response to exhaustive exercise in patients with chronic obstructive pulmonary disease. Respir Med 2005;99:1555-1567.
27. Aronson D, Roterman I, Yigla M, Kerner A, Avizohar O, Sella R, Bartha P, Levy Y, Markiewicz W. Inverse association between pulmonary function and C-reactive protein in apparently healthy subjects. Am J Respir Crit Care Med 2006;174:626-632.
28. Shaaban R, Kony S, Driss F, Leynaert B, Soussan D, Pin I, Neukirch F, Zureik M. Change in C-reactive protein levels and FEV(1) decline: a longitudinal population-based study. Respir Med 2006;100:2112-2120.
29. Yende S, Waterer GW, Tolley EA, Newman AB, Bauer DC, Taaffe DR, Jensen R, Crapo R, Rubin S, Nevitt M, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006;61:10-16.
30. Schols AMW, Buurman WA, Staal-van den Brekel AJ, Dentener MA, Wouters EFM. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996;51:819-824.
31. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Elevated CRP mark metabolic and functional impairment in advanced COPD. Thorax 2006;61:17-22.
32. Sin DD, Man SFP. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? Circulation 2003;107:1514-1519.
33. Lapperre TS, Snoeck-Stroband JB, Gosman MME, Stolk J, Sont JK, Jansen DF, Kerstjens HAM, Postma DS, Sterk PJ. Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:499-504.
34. Yoshida M, Sakuma J, Hayashi S, Abe K, Saito I, Harada S, Sakatani M, Yamamoto S, Matsumoto N, Kaneda Y, et al. A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor β1, or platelet-derived growth factor B gene. Proc Natl Acad Sci USA 1995;92:9570-9574.
35. Hierholzer C, Kalff JC, Omert L, Tsukada K, Loeffert JE, Watkins SC, Billiar TR, Tweardy DJ. Interleukin-6 production in hemorrhagic shock is accompanied by neutrophil recruitment and lung injury. Am J Physiol 1998;275:L611-L621.
36. Park CS, Chung SW, Ki SY, Lim GI, Uh ST, Kim YH, Choi DI, Park JS, Lee DW, Kitaichi M. Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic nonspecific interstitial pneumonia. Am J Respir Crit Care Med 2000;162:1162-1168.
37. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1008-1011.
38. Welle I, Bakke PS, Eide GE, Fagerhol MK, Omenaas E, Gulsvik A. Increased circulating levels of alpha1-antitrypsin and calprotectin are associated with reduced gas diffusion in the lungs. Eur Respir J 2001;17:1105-1111.
39. Xing Z, Braciak T, Jordana M, Croitoru K, Graham FL, Gauldie J. Adenovirus-mediated cytokine gene transfer at tissue sites: overexpression of IL-6 induces lymphocytic hyperplasia in the lung. J Immunol 1994;153:4059-4069.
40. DiCosmo BF, Geba GP, Picarella D, Elias JA, Rankin JA, Stripp BR, Whitsett JA, Flavell RA. Airway epithelial cell expression of interleukin-6 in transgenic mice. Uncoupling of airway inflammation and bronchial hyperreactivity. J Clin Invest 1994;94:2028-2035.
41. + T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J Exp Med 1996;183:1345-1355.
42. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, Faggioni R, Luini W, van Hinsbergh V, Sozzani S, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997;6:315-325.
43. Suwa T, Hogg JC, Klut ME, Hards J, van Eeden SF. Interleukin-6 changes deformability of neutrophils and induces their sequestration in the lung. Am J Respir Crit Care Med 2001;163:970-976.
44. Johnston RA, Schwartzman IN, Flynt L, Shore SA. Role of interleukin-6 in murine airway responses to ozone. Am J Physiol Lung Cell Mol Physiol 2005;288:L390-L397.
45. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba F, Coxson HO, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653.
46. Kuhn C 3rd, Homer RJ, Zhu Z, Ward N, Flavell RA, Geba GP, Elias JA. Airway hyperresponsiveness and airway obstruction in transgenic mice. Morphologic correlates in mice overexpressing interleukin (IL)-11 and IL-6 in the lung. Am J Respir Cell Mol Biol 2000;22:289-295.
47. Janssen SP, Gayan-Ramirez G, Van den Bergh A, Herijgers P, Maes K, Verbeken E, Decramer M. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation 2005;111:996-1005.
48. Yu M, Zheng X, Witschi H, Pinkerton KE. The role of interleukin-6 in pulmonary inflammation and injury induced by environmental air pollutants. Toxicol Sci 2002;68:488-497.
49. Sin DD, Lacy P, York E, Man SFP. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:760-765.